Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New blood test aims to catch live prostate cancer cells

NCT ID NCT04581109

Diagnosis Sponsor: University Hospital, Montpellier Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new blood test called EPIDROP that looks for live circulating tumor cells in men with metastatic prostate cancer. The test uses a special technique to isolate single cells and measure their activity. Researchers want to see if EPIDROP is as good as or better than the current standard test, CellSearch. The study involves 100 men with metastatic prostate cancer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
EPIDROP blood test
What this could lead to
If successful, this could provide a more accurate and sensitive way to detect circulating tumor cells, helping guide treatment decisions for prostate cancer.
What could go wrong
This is an early-stage diagnostic study with 100 participants, so results may not be definitive or widely applicable. The new test may not prove better than the existing method.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

100 people

The number who actually took part.

Started

May 2021

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria : * To be male, over 18 years old * Metastatic prostate cancer naive to any treatment or metastatic prostate cancer in biological recurrence (PSA increase) and/or clinical recurrence after hormone suppression (mCRPC) Exclusion Criteria: * Non-metastatic prostate cancer in biological and/or clinical recurrence after hormone-suppression (nmCRPC) * Other active or treated cancer less than 5 years old * Be protected by law (guardianship or curatorship) * Be deprived of liberty by administrative decision * Not being affiliated to a social security scheme, or not being a beneficiary of such a plan * Being in a period of exclusion from another protocol * Inability to understand and/or respond to questionnaires * Inability to understand the nature, purpose and methodology of the study * Refusal to sign informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic prostate cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma Neoplastic Cells, Circulating prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate cancer

Contacts and locations

Locations

  • University Center, Hospital

    Nîmes, France

  • University Hospital Center

    Montpellier, Occitanie, 34295, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.